Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

The prevalence of food allergy is significantly lower in children with cystic fibrosis than in those without the condition in ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated ...

Two brothers and two friends take on and wi, an 80-mile Atlantic paddleboard challenge in an effort to provide support for ...

Most children with CF treated at a San Francisco CF clinic did not receive CF liver disease screening in accordance with current guidelines.

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

North Carolina man created a foundation to help other patients navigate expenses of an unexpectedly longer life ...

A small group of Australians with the rarest kinds of cystic fibrosis – fewer than 200 people – will, for the first time, ...

Affordable access to life-changing treatment for cystic fibrosis will be expanded to more Australians with a change to the ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

Ben is running 12 marathons in 12 months to raise awareness for cystic fibrosis, a condition he's battled since childhood.